In patients with type 2 diabetes and high cardiovascular risk, once-weekly semaglutide significantly reduced the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared to placebo, though it was associated with a higher risk of diabetic retinopathy complications.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
CATEGORIES
© 2024-2026 Hormone Insight. All rights reserved.